

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Protocol for a longitudinal cohort study: Determination of risk factors for the development of first venous leg ulcer in people with chronic venous insufficiency, the VEINS (Venous Insufficiency in South Florida) Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023313
Article Type:	Protocol
Date Submitted by the Author:	31-Mar-2018
Complete List of Authors:	Mervis, Joshua; University of Miami School of Medicine, Dermatology and Cutaneous Surgery Kirsner, Robert; University of Miami School of Medicine, Dermatology and Cutaneous Surgery Lev-Tov, Hadar; University of Miami School of Medicine, Dermatology and Cutaneous Surgery
Keywords:	Chronic venous insufficiency, Venous leg ulcer, Longitudinal cohort study, Primary prevention

SCHOLARONE™
Manuscripts

Protocol for a longitudinal cohort study: Determination of risk factors for the development of first venous leg ulcer in people with chronic venous insufficiency, the VEINS (Venous Insufficiency in South Florida) Cohort

Joshua Mervis¹, B.A.; Robert S. Kirsner¹, M.D.; Ph.D.; Hadar Lev-Tov¹, M.D.

¹Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida

*Address for correspondence:

Hadar Lev-Tov, M.D.
Department of Dermatology & Cutaneous Surgery
University of Miami Miller School of Medicine
1600 NW 10th Avenue, Room 2023A
Miami, FL, 33136
U.S.A.
Phone: 305-243-6734
Email: hlevtov@med.miami.edu

Word Count: 2,570

Reference Count: 26

Figure Count: 1

Table Count: 2

Funding Sources: This study received NO specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest: The authors of this protocol have NO conflict of interest to declare.

Prior Presentation: The authors declare that this protocol has NOT been published previously.

Abstract:

Introduction: Chronic venous insufficiency (CVI) affects up to one third of the adult population yet venous leg ulcers (VLU), a significant complication of CVI, only affect 1-2% of adults in the United States. Why some develop VLU and others do not is unclear. VLU have a significant impact on quality of life and are extremely costly and difficult to treat. Moreover, VLU prevalence is increasing, doubling in the last 20 years. In order to characterize the differences between people with CVI and those who ultimately develop VLU, we aim to set up the unique Venous Insufficiency in South Florida (VEINS) cohort.

Methods and analysis: Subjects will be recruited from the University of Miami Hospital and Clinic's vascular lab database, which began in July 2011. Any adult age 18-95 who has had venous reflux detected on duplex ultrasound of the lower extremities is included. Approximately 2,500 patients are already in the database that meet these criteria, with an estimated 2,500 additional potential subjects to be recruited from the vascular lab database over the next five years. Subjects with history of VLU prior to duplex study date will be excluded. Data will be collected via review of the Doppler study report, patient phone interview, and review of the electronic medical record. Subjects will be contacted for follow-up every 3 months for at least 5 years until the study endpoint, development of first VLU (fVLU), is reached. In order to estimate the time from reflux documentation to fVLU, Kaplan Meier survival curves will be constructed. Cox proportional hazard regression models will be constructed to investigate possible risk factors.

1
2
3 **Ethics and dissemination:** This study is approved by the University of Miami's
4 Institutional Review Board (IRB). We hope to present the results of this study to
5
6 the scientific community at conferences and in peer-reviewed journals.
7
8
9

10
11
12
13
14
15 **Keywords:** Venous leg ulcer, Chronic venous insufficiency, primary prevention,
16 cohort study
17
18
19
20
21
22
23
24
25

26 **Strengths and Limitations:**

- 27
28 • To our knowledge, this study is the first that seeks to prospectively track
29 development of the fVLU among a population of subjects with CVI.
30
31
- 32 • The VEINS cohort will describe the natural history of CVI leading to fVLU, reveal
33 specific risk factors for the development of fVLU, and allow for the development
34 of 3- and 5-year predictive models for fVLU occurrence.
35
36
- 37 • The data obtained from this study will support the development of VLU
38 prevention strategies.
39
40
- 41 • This study does not address time in relation to initial development of CVI, but
42 rather time from documentation of CVI on venous duplex ultrasound, typically the
43 point at which CVI becomes clinically significant.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protocol for a longitudinal cohort study: Determination of risk factors for the development of first venous leg ulcer in people with chronic venous insufficiency, the VEINS (Venous Insufficiency in South Florida) Cohort

Introduction

Background:

Chronic ulcers of the lower extremities affect 1-2% of adults in the United States (1-3). Of these ulcers, around 70% are due to venous disease alone, while 20% are due to arterial or mixed arteriovenous disease (2). Venous leg ulcers (VLU) are wounds that typically occur on the lower third of the leg between the ankle and knee, often referred to as the “gaiter area,” in the setting of chronic venous insufficiency (CVI). In the United States, roughly a third of the adult population is likely to have CVI, while worldwide prevalence estimates are up to 60% (4). CVI is characterized by sustained ambulatory venous pressure (aka venous hypertension) and by reflux on Doppler ultrasound. Reflux is defined as retrograde blood flow in the lower extremities greater than 0.5 seconds while in the reverse Trendelenburg position without provocation. Typical causes of CVI include obstruction from deep vein thrombosis, valvular defects, which may be acquired or genetic, and ineffective calf muscle pump action (1, 2). The pathophysiology of VLU remains unclear, though various hypotheses implicating pericapillary fibrin cuffing, endovascular trapping of oxygen and nutrients, inflammatory cell infiltrates, cytokine trapping, and metalloproteinase dysregulation have all been areas of extensive research (5-7).

1
2
3 VLU often have a very significant impact on a patient's quality of life (8). Compared with
4
5 matched controls, patients with VLU have more comorbid conditions, miss more days of work,
6
7 and use more medical resources (9, 10). While numerous advancements in treatment, such as
8
9 cellular and acellular skin equivalents and biomaterials, have been made in recent years (1),
10
11 VLU prevalence seems to be increasing. The estimated prevalence of VLU has doubled in the
12
13 last 20 years from 0.3% to 0.6% in adults under 65 and is up to 2.2% in adults over 65 (9, 11).
14
15 European epidemiologic data has shown similar prevalence rates among these age groups,
16
17 while revealing that VLU prevalence is even higher at 4-5% in individuals older than 80 years
18
19 (12) and may exceed 12% among certain elderly populations. (13)
20
21
22
23
24

25 Moreover, the costs associated with VLU have been increasing and represent a great
26
27 burden for both the patient and public health system. Over the last 30 years, the estimated cost
28
29 of treating a single, chronic VLU has more than tripled to \$34,000 today (9, 11). Likewise, the
30
31 annual cost of VLU treatment in the United States has risen from around \$3 billion in 1987 to
32
33 \$15 billion in 2011 ((10).
34
35
36
37
38
39

40 **Rationale:**

41
42 With an aging population, it is likely that VLU prevalence will continue to rise, with more
43
44 ulcers occurring in older, sicker patients who are costlier to treat. Despite the significant
45
46 morbidity, high costs, and continued difficulty in healing of VLU, little attention has been given
47
48 to primary prevention. Thus, a paradigm shift, away from wholesale investment in advanced
49
50 interventions and toward prevention, is warranted. The idea that a greater emphasis on VLU
51
52 prevention is needed is not new, going back to at least 1997 (14). Nonetheless, no studies to
53
54
55
56
57
58
59
60

1
2
3 date have focused on prevention of the first VLU (fVLU). Without this data, society and
4
5 summary guidelines on VLU have not been able to make recommendations regarding primary
6
7 prevention (1, 2, 15, 16).
8
9

10
11 Given that the pathophysiology of VLUs is not well-understood, risk factor analysis is a
12
13 sensible strategy for studying prevention. With the goals of developing a predictive model for
14
15 ulceration and overall prevention strategy in mind, this study aims to identify risk factors
16
17 associated with development of the fVLU. While certain risk factors have been described (Table
18
19 1), they are based primarily on either retrospective analyses that compared people with any
20
21 VLU (i.e. first or recurrent) to the general population or on expert opinion.
22
23

24
25 Furthermore, associations between VLU occurrence and certain medical conditions (17),
26
27 medications (18, 19), and other parameters (20-22) have been made, but the directionality of
28
29 the association is not clear. Although these data are informative, they may not be clinically
30
31 useful. A need exists to distinguish risk factors for CVI and for fVLU, as a only a small minority of
32
33 patients with CVI proceed to develop a fVLU (23). Particular risk factors specific for the fVLU are
34
35 not known, and to our knowledge no study has prospectively tracked development of the fVLU.
36
37

38
39 Therefore, the primary aim of this research is to answer a simple yet extremely complex
40
41 clinical question: in a patient presenting with signs and symptoms of CVI, what interventions
42
43 may prevent a fVLU?
44
45

46 47 48 49 **Primary Objective**

- 50
51
52 1. Characterize risk factors associated with developing fVLU in people with CVI.
53
54
55
56
57
58
59
60

Secondary Objectives

2. Develop 3- and 5-year predictive models for risk of developing fVLU in patients with signs and symptoms of CVI.
3. Estimate the incidence of fVLU in people with CVI.

Methods and Analysis:

Geographical Context

Subjects will represent a diverse group from all over southeastern Florida primarily, with the vast majority coming from Miami-Dade, Broward, and Palm Beach Counties in the United States.

Study population

The VEINS Cohort will include both men and women ages 18-95. Any adult who has had reflux detected on venous duplex ultrasound of the lower extremities is potentially eligible. Patients who have undergone venous duplex studies for any indication will be considered. Exclusion criteria include age under 18, inability to provide consent over the phone, and history of venous ulcer prior to duplex study date.

Recruitment of Participants

1
2
3 Subjects will be recruited from a database of the University of Miami Hospital
4 and Clinic's vascular laboratory. The database, which goes back to July 2011, will be
5
6 queried for all patients who were found to have reflux on venous duplex ultrasound of
7
8 the lower extremities. After reflux has been noted from the duplex study report, the
9
10 subject's chart will be reviewed in the Electronic Medical Record (EMR) to ascertain
11
12 basic contact information. For this part of the study, a privacy waiver for recruitment
13
14 purposes has been approved by the local institutional review board (IRB). The
15
16 investigators will then call potential subjects by phone. The subjects will provide a verbal
17
18 phone consent for a phone survey and further chart review of potential risk factors.
19
20 During the verbal informed consent, all aspects of the study will be reviewed, including:
21
22 why subjects were selected, researcher goals, procedures, relevant risks, benefits, and
23
24 subjects' rights. It is anticipated that a large portion of the study population is Spanish
25
26 speaking. The verbal informed consent and survey have both been translated to Spanish
27
28 and will be administered by Spanish speaking research staff, with the help of an
29
30 interpreter as needed. Once consent is obtained and inclusion criteria confirmed,
31
32 subjects will be enrolled into the cohort.
33
34
35
36
37
38
39
40
41
42
43
44

45 **Sample size**

46
47 There are approximately 2,500 lower extremity venous duplex ultrasound reports in the
48
49 database that detected reflux going back to its inception in July 2011. In recent years,
50
51 approximately 500 duplex studies that find reflux have been performed annually. Thus, over the
52
53 next 5 years, we expect approximately 2,500 additional subjects will be potentially eligible to
54
55
56
57
58
59
60

1
2
3 enter the cohort. Given the paucity of data available on the incidence of fVLU, we will attempt
4
5 to recruit as many subjects as possible.
6
7
8
9

10 **Study design – Overview**

11
12 This protocol is for a longitudinal cohort study with retrospective and prospective
13 components. The methodology for building the cohort and following subjects is outlined in
14
15 **Figure 1.** The aim throughout is to identify subjects with venous reflux documented on
16 ultrasound prior to the development of fVLU. Any subject who reports a history of an ulcer
17 prior to the date of reflux study will be excluded from the cohort. The retrospective part of the
18 study will cover all patients currently in the database. If a subject went on to develop a fVLU
19 subsequent to the time of duplex study (i.e. after reflux was documented but before first
20 contact by the investigators), he/she will not be followed in any prospective manner. Instead,
21 only an entry survey will be administered (see below for details) and the subject's participation
22 will end. The prospective part of this study will include any subject who met inclusion criteria
23 but has not yet developed a VLU. Regardless of when subjects enter the cohort, they will be
24 followed prospectively for five years from the beginning of the study or the occurrence of an
25 ulcer, whichever occurs first. Any subject who begins in the retrospective cohort can continue
26 into the prospective cohort so long as the fVLU has not developed. Currently, there is no pre-
27 determined stop date after which new subjects will cease to be recruited for the cohort. New
28 subjects will continuously be recruited as new patients come through the vascular lab for
29 venous studies.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

End Point and Follow-up

The endpoint of this study is development of fVLU, after which subjects will exit the cohort. If a subject has no history of fVLU, he/she will be contacted by phone for a follow-up survey every 3 months until the development of fVLU. At this time, the intention is that subjects will be followed for at least 5 years.

Data collection and management

In all cases, data will be collected via three sources: venous duplex ultrasound report, phone survey, and patient chart in the EMR. Venous duplex ultrasound reports will be accessed from a secure electronic database housed in the University of Miami Hospital and Clinic's vascular laboratory. For the phone survey, a script with exact wording for all questions and instructions has been created. Data on specific variables of interest will be ascertained from each source as outlined in Table 2.

All data will be entered and stored electronically in REDCap (Research Electronic Data Capture), a secure, web-based application that facilitates creation and management of data collection instruments, monitoring of data quality, and statistical analysis of data (24). This software has commonly been used for epidemiological research, including similar cohort studies (25). All investigators will be trained in data entry by the REDCap study administrator and must demonstrate proficiency with mock patients and data entry before being granted access to data collection forms.

Evaluation of study endpoint – photo of wound

1
2
3 If a subject reports development of fVLU, investigators will seek to obtain a photo in the
4 patient chart or request that the subject submits a picture of the wound via email. While not
5
6 patient chart or request that the subject submits a picture of the wound via email. While not
7
8 required by the study protocol, a photograph can help validate that the wound is a VLU. In
9
10 cases where visual evidence is not available, ulcer validation will be supported by key questions
11
12 regarding the wound, such as location and duration. Moreover, there is data supporting the
13
14 ability of patients to correctly self-assess the status of their chronic wounds with up to 97%
15
16 accuracy when compared to expert evaluation (26).
17
18
19
20
21
22

23 **Pilot Study**

24
25 A pilot study of 70 potential subjects was carried out. The first 10 venous duplex studies
26
27 to report reflux from each year of the database's existence (2011-2017) were used. The
28
29 purpose of this pilot study was to give investigators the chance to determine how well the
30
31 phone survey and data collection forms performed with a variety of real subjects, and to
32
33 discuss any changes that should be made. Only minor technical changes in data coding were
34
35 made. Of the 70 patients that were called, 22 were reached over the phone, 20 of whom
36
37 enrolled in the study.
38
39
40
41
42
43
44
45
46
47
48
49

50 **Statistical analysis of data**

51
52
53 For purpose of analysis the data will be de-identified and exported from Redcap into IBM SPSS
54
55 Statistics for Windows (IBM Corporation, Armonk, NY, USA). Summary estimate and confidence
56
57
58
59
60

1
2
3 intervals will be calculated. In order to estimate the time from venous reflux documentation to
4
5 fVLU, Kaplan Meier survival curves will be constructed. Cox proportional hazard regression
6
7
8 models will be constructed to investigate possible risk factors.
9
10
11
12
13
14
15
16

17 Discussion

18
19
20 The aim of this study is to develop a cohort of patients with proven venous reflux that
21
22 can be followed prospectively until the development of a venous leg ulcer. In doing so, we hope
23
24 to shed some light on who, of the millions of people with CVI, is at greatest risk of developing a
25
26 fVLU. Previous studies have looked at recurrence rates and associated risk factors regarding
27
28 venous ulcers, but data regarding fVLU is quite limited. In addition, VLU incidence data
29
30 collected from the cohort will be informative, as the only incidence data available has been
31
32 inferred from retrospective analyses. The VEINS Cohort study seeks to determine, in a
33
34 prospective fashion, the roles of traditional CVI risk factors and novel risk or protective factors
35
36 in the development of fVLU. Where associations are detected, further studies will be pursued
37
38 that seek to elucidate the nature of the association. Furthermore, in identifying particular risk
39
40 factors and/or protective factors, we hope to develop a predictive model with risk scores for
41
42 the likelihood of fVLU development within 3 and 5 years of clinically significant CVI. Of note,
43
44 this study does not address time in relation to initial development of CVI, but rather time from
45
46 documentation of CVI on venous duplex ultrasound. Though lead time bias could impact our
47
48 analyses, lower extremity ultrasounds looking for reflux are typically only performed when CVI
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 becomes clinically significant, which is usually concurrent with the first time a patient sees a
4
5
6 doctor for leg problems.
7

8 Implementing early interventions that delay or prevent the development of a chronic
9
10 and morbid condition is the guiding principle behind these efforts. In doing so, the whole of
11
12 society benefits both economically and socially from a happier and healthier population.
13
14

15 16 17 18 **Potential Benefit to subjects:**

19
20 While there is no direct benefit to subjects, being asked about their health status
21
22 by a member of the research team every three months may raise the subjects'
23
24 awareness of their health. Additionally, if a patient develops an ulcer while in the
25
26 cohort, he/she will be referred to a wound clinic for appropriate management and
27
28 wound care.
29
30
31
32
33
34
35

36 37 38 ***Ethics and Dissemination:***

39 40 **Ethical aspects**

41 The Primary Investigator has extensive training and experience in clinical research and
42
43 relevant bioethics. The research staff will include a team of primary researchers that have
44
45 extensive qualifications and expertise to lead the study. All study staff are trained and routinely
46
47 re-educated about the ethical conduct of human subject research. There are no anticipated
48
49 physical, social, legal or economic risks associated with the study. There is minimal risk of
50
51 breach of confidentiality. No vulnerable populations are specifically targeted in this study.
52
53
54
55
56 Pregnant women will not be excluded.
57
58
59
60

Data protection

All subject-specific data will be kept confidential in a password-protected University desktop that can only be accessed by investigators. Study offices are kept locked and are protected by around-the-clock University of Miami security services. All records containing personal health information will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available. De-identified collected data may be used for future analysis and publication.

Dissemination

We hope to present the results of this study to the scientific community at conferences and in peer-reviewed journals.

Table 1: Risk factors for VLU (Vivas *et al.*, 2016)(1)

Age older than 55 years
Family history of CVI
Higher body mass index
History of pulmonary embolism
History of superficial/deep venous thrombosis
Lower extremities skeletal or joint disease
Number of pregnancies
Parental history of ankle ulcers
Physical inactivity
Ulcer history
Severe lipodermatosclerosis
Venous reflux in deep veins

VLU = venous leg ulcer

CVI = chronic venous insufficiency

For peer review only

Table 2: Variables of interest with corresponding data source

<i>Venous duplex ultrasound report:</i>	<i>Phone survey:</i>	<i>Patient chart:</i>
Study date	Race	Sex
Study indication	Ethnicity	Height
Reflux location(s)	History of VLU (including ulcer start date)	Weight
Reflux time(s)	Limitation of ankle movement	Venous dermatitis
Presence of DVT or superficial vein thrombosis	Mobility (i.e. use of a wheelchair or walker)	Lipodermatosclerosis
	History of DVT or PE	Atrophie blanche
	History of varicose veins	Past medical and surgical history
	History of leg swelling	Ulcer photograph
	Chronic itch of lower extremities	
	Chronic rash of lower extremities	
	Lower extremity vein procedures	
	Lower extremity artery procedures	
	Use of compression on lower extremities	
	Elevation of legs when sleeping	
	Number of pregnancies	
	Other past medical and surgical history	
	Medications	
	Smoking history	
	Exercise	
	Family history of leg ulcers, swelling, or varicose veins	

VLU = venous leg ulcer

DVT = deep vein thrombosis

PE = pulmonary embolism




Figure 1: Flowchart outlining the methodology for building the VEINS cohort and following subjects prospectively once they are enrolled

References:

1. Vivas A, Lev-Tov H, Kirsner RS. Venous Leg Ulcers. *Ann Intern Med.* 2016;165(3):ITC17-ITC32.
2. Alavi A, Sibbald RG, Phillips TJ, Miller OF, Margolis DJ, Marston W, et al. What's new: Management of venous leg ulcers: Approach to venous leg ulcers. *J Am Acad Dermatol.* 2016;74(4):627-40; quiz 41-2.
3. Singer AJ, Tassiopoulos A, Kirsner RS. Evaluation and Management of Lower-Extremity Ulcers. *N Engl J Med.* 2017;377(16):1559-67.
4. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F, Coordinators V. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. *Int Angiol.* 2012;31(2):105-15.
5. Liu YC, Margolis DJ, Isseroff RR. Does inflammation have a role in the pathogenesis of venous ulcers? A critical review of the evidence. *J Invest Dermatol.* 2011;131(4):818-27.
6. Van de Scheur M, Falanga V. Pericapillary fibrin cuffs in venous disease. A reappraisal. *Dermatol Surg.* 1997;23(10):955-9.
7. Falanga V, Kirsner R, Katz MH, Gould E, Eaglstein WH, McFalls S. Pericapillary fibrin cuffs in venous ulceration. Persistence with treatment and during ulcer healing. *J Dermatol Surg Oncol.* 1992;18(5):409-14.
8. Green J, Jester R, McKinley R, Pooler A. The impact of chronic venous leg ulcers: a systematic review. *J Wound Care.* 2014;23(12):601-12.
9. Ma H, O'Donnell TF, Rosen NA, lafrati MD. The real cost of treating venous ulcers in a contemporary vascular practice. *J Vasc Surg Venous Lymphat Disord.* 2014;2(4):355-61.
10. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N. Burden of venous leg ulcers in the United States. *J Med Econ.* 2014;17(5):347-56.
11. Kurz X, Kahn SR, Abenheim L, Clement D, Norgren L, Baccaglini U, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. *Venous Insufficiency Epidemiologic and Economic Studies.* *Int Angiol.* 1999;18(2):83-102.
12. Neumann HA, Cornu-Thénard A, Jünger M, Mosti G, Munte K, Partsch H, et al. Evidence-based (S3) guidelines for diagnostics and treatment of venous leg ulcers. *J Eur Acad Dermatol Venereol.* 2016.
13. Marklund B, Sülau T, Lindholm C. Prevalence of non-healed and healed chronic leg ulcers in an elderly rural population. *Scand J Prim Health Care.* 2000;18(1):58-60.
14. Maklebust JA, Margolis DJ. Venous leg ulcer risk factors: who will study the problem? *Adv Wound Care.* 1997;10(2):6, 8.
15. Burrows C, Miller R, Townsend D, Bellefontaine R, Mackean G, Orsted HL, et al. Best practice recommendations for the prevention and treatment of venous leg ulcers: update 2006. *Adv Skin Wound Care.* 2007;20(11):611-21; quiz 22-3.
16. Robson MC, Cooper DM, Aslam R, Gould LJ, Harding KG, Margolis DJ, et al. Guidelines for the prevention of venous ulcers. *Wound Repair Regen.* 2008;16(2):147-50.
17. Margolis DJ, Knauss J, Bilker W. Medical conditions associated with venous leg ulcers. *Br J Dermatol.* 2004;150(2):267-73.

- 1
2
3 18. Margolis DJ, Hoffstad O, Isseroff RR. Association between the use of beta-adrenergic
4 receptor agents and the development of venous leg ulcers. *Arch Dermatol*. 2007;143(10):1275-
5 80.
6
7 19. Bérard A, Kahn SR, Abenham L. Is hormone replacement therapy protective for venous
8 ulcer of the lower limbs? *Pharmacoepidemiol Drug Saf*. 2001;10(3):245-51.
9
10 20. Abbade LP, Lastória S, Rollo HeA. Venous ulcer: clinical characteristics and risk factors.
11 *Int J Dermatol*. 2011;50(4):405-11.
12
13 21. Robertson L, Lee AJ, Gallagher K, Carmichael SJ, Evans CJ, McKinstry BH, et al. Risk
14 factors for chronic ulceration in patients with varicose veins: a case control study. *J Vasc Surg*.
15 2009;49(6):1490-8.
16
17 22. Vlajinac H, Marinkovic J, Maksimovic M, Radak D. Factors related to venous ulceration: a
18 cross-sectional study. *Angiology*. 2014;65(9):824-30.
19
20 23. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic
21 venous insufficiency in men and women in the general population: Edinburgh Vein Study. *J*
22 *Epidemiol Community Health*. 1999;53(3):149-53.
23
24 24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
25 capture (REDCap)--a metadata-driven methodology and workflow process for providing
26 translational research informatics support. *J Biomed Inform*. 2009;42(2):377-81.
27
28 25. Blumenberg C, Barros AJ. Electronic data collection in epidemiological research. The use
29 of REDCap in the Pelotas birth cohorts. *Appl Clin Inform*. 2016;7(3):672-81.
30
31 26. Yim E, Van Driessche F, Baquerizo Nole KL, Kirsner RS. Patient self-assessment of chronic
32 wounds. *Wound Repair Regen*. 2014;22(5):683-4.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Protocol for a longitudinal cohort study: Determination of risk factors for the development of first venous leg ulcer in people with chronic venous insufficiency, the VEINS (Venous Insufficiency in South Florida) Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023313.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Aug-2018
Complete List of Authors:	Mervis, Joshua; University of Miami School of Medicine, Dermatology and Cutaneous Surgery Kirsner, Robert; University of Miami School of Medicine, Dermatology and Cutaneous Surgery Lev-Tov, Hadar; University of Miami School of Medicine, Dermatology and Cutaneous Surgery
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Dermatology, General practice / Family practice, Surgery, Cardiovascular medicine
Keywords:	Chronic venous insufficiency, Venous leg ulcer, Longitudinal cohort study, Primary prevention, venous reflux

SCHOLARONE™
Manuscripts

Protocol for a longitudinal cohort study: Determination of risk factors for the development of first venous leg ulcer in people with chronic venous insufficiency, the VEINS (Venous Insufficiency in South Florida) Cohort

Joshua Mervis¹, B.A.; Robert S. Kirsner¹, M.D.; Ph.D.; Hadar Lev-Tov¹, M.D.

¹Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida

*Address for correspondence:

Hadar Lev-Tov, M.D.
Department of Dermatology & Cutaneous Surgery
University of Miami Miller School of Medicine
1600 NW 10th Avenue, Room 2023A
Miami, FL, 33136
U.S.A.
Phone: 305-243-6734
Email: hlevtov@med.miami.edu

Word Count: 2,646

Reference Count: 27

Figure Count: 1

Table Count: 2

Funding Sources: This study received NO specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest: The authors of this protocol have NO conflict of interest to declare.

Prior Presentation: The authors declare that this protocol has NOT been published previously.

Contributorship Statement: All authors, including Joshua S. Mervis, Robert S. Kirsner, and Hadar Lev-Tov, made substantial contributions to the conception and design of this

1
2
3 protocol. All authors have critically read this manuscript and have made their revisions,
4
5 and they have now all approved this final version for submission. All authors agree to be
6
7 accountable for the future integrity of this study.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract:

Introduction: Chronic venous insufficiency (CVI) affects up to one third of the adult population yet venous leg ulcers (VLU), a significant complication of CVI, only affect 1-2% of adults in the United States. Why some develop VLU and others do not is unclear. VLU have a significant impact on quality of life and are extremely costly and difficult to treat. Moreover, VLU prevalence is increasing, doubling in the last 20 years. In order to characterize the differences between people with CVI and those who ultimately develop VLU, we aim to set up the unique Venous Insufficiency in South Florida (VEINS) cohort.

Methods and analysis: Subjects will be recruited from the University of Miami Hospital and Clinic's vascular lab database, which began in July 2011. Any adult age 18-95 who has had venous reflux detected on duplex ultrasound of the lower extremities is included. Approximately 2,500 patients are already in the database that meet these criteria, with an estimated 2,500 additional potential subjects to be recruited from the vascular lab database over the next five years. Subjects with history of VLU prior to duplex study date will be excluded. Data will be collected via review of the Doppler study report, patient phone interview, and review of the electronic medical record. Subjects will be contacted for follow-up every 3 months for at least 5 years until the study endpoint, development of first VLU (fVLU), is reached. In order to estimate the time from reflux documentation to fVLU, Kaplan Meier survival curves will be constructed. Cox proportional hazard regression models will be constructed to investigate possible risk factors.

1
2
3 **Ethics and dissemination:** This study is approved by the University of Miami's
4 Institutional Review Board (IRB). We hope to present the results of this study to
5
6 the scientific community at conferences and in peer-reviewed journals.
7
8
9

10
11
12
13
14
15 **Keywords:** Venous leg ulcer, Chronic venous insufficiency, primary prevention,
16 cohort study
17
18
19

20 21 22 23 24 25 **Strengths and Limitations:**

- 26
27
28 • To our knowledge, this study is the first that seeks to prospectively track
29 development of the fVLU among a population of subjects with CVI.
30
31
- 32
33 • The VEINS cohort will describe the natural history of CVI leading to fVLU, reveal
34 specific risk factors for the development of fVLU, and allow for the development
35 of 3- and 5-year predictive models for fVLU occurrence.
36
37
- 38
39 • The data obtained from this study will support the development of VLU
40 prevention strategies.
41
42
- 43
44 • This study does not address time in relation to initial development of CVI, but
45 rather time from documentation of CVI on venous duplex ultrasound, typically the
46 point at which CVI becomes clinically significant.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protocol for a longitudinal cohort study: Determination of risk factors for the development of first venous leg ulcer in people with chronic venous insufficiency, the VEINS (Venous Insufficiency in South Florida) Cohort

Introduction

Background:

Chronic ulcers of the lower extremities affect 1-2% of adults in the United States (1-3). Of these ulcers, around 70% are due to venous disease alone, while 20% are due to arterial or mixed arteriovenous disease (2). Venous leg ulcers (VLU) are wounds that typically occur on the lower third of the leg between the ankle and knee, often referred to as the “gaiter area,” in the setting of chronic venous insufficiency (CVI). In the United States, roughly a third of the adult population is likely to have CVI, while worldwide prevalence estimates are up to 60% (4). CVI is characterized by sustained ambulatory venous pressure (aka venous hypertension) and by reflux on Doppler ultrasound. Reflux is typically defined as retrograde blood flow in the lower extremities greater than 0.5 seconds after provocation (5). Typical causes of CVI include valvular defects, which may be acquired or genetic, ineffective calf muscle pump action, and obstruction from deep vein thrombosis (1, 2). The pathophysiology of VLU remains unclear, though various observation-based hypotheses implicating pericapillary fibrin cuffing, endovascular trapping of oxygen and nutrients, inflammatory cell infiltrates, cytokine trapping, and metalloproteinase dysregulation have all been areas of extensive research (6-8).

1
2
3 VLU often have a very significant impact on a patient's quality of life (9). Compared with
4
5
6 matched controls, patients with VLU have more comorbid conditions, miss more days of work,
7
8
9 and use more medical resources (10, 11). While numerous advancements in treatment, such as
10
11
12 cellular and acellular skin equivalents and biomaterials, have been made in recent years (1),
13
14
15 VLU prevalence seems to be increasing. The estimated prevalence of VLU has doubled in the
16
17
18 last 20 years from 0.3% to 0.6% in adults under 65 and is up to 2.2% in adults over 65 (10, 12).
19
20
21 European epidemiologic data has shown similar prevalence rates among these age groups,
22
23
24 while revealing that VLU prevalence is even higher at 4-5% in individuals older than 80 years
25
26
27 (13) and may exceed 12% among certain elderly populations. (14)

28
29
30 Moreover, the costs associated with VLU have been increasing and represent a great
31
32
33 burden for both the patient and public health system. Over the last 30 years, the estimated cost
34
35
36 of treating a single, chronic VLU has more than tripled to \$34,000 today (10, 12). Likewise, the
37
38
39 annual cost of VLU treatment in the United States has risen from around \$3 billion in 1987 to
40
41
42 \$15 billion in 2011 ((11).

43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 **Rationale:**

61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

With an aging population, it is likely that VLU prevalence will continue to rise, with more
ulcers occurring in older, sicker patients who are costlier to treat. Despite the significant
morbidity, high costs, and continued difficulty in healing of VLU, little attention has been given
to primary prevention. Thus, a paradigm shift, away from wholesale investment in advanced
interventions and toward prevention, is warranted. The idea that a greater emphasis on VLU
prevention is needed is not new, going back to at least 1997 (15). Nonetheless, no studies to

1
2
3 date have focused on prevention of the first VLU (fVLU). Without this data, society and
4
5 summary guidelines on VLU have not been able to make recommendations regarding primary
6
7 prevention (1, 2, 16, 17).
8
9

10
11 Given that the pathophysiology of VLUs is not well-understood, risk factor analysis is a
12
13 sensible strategy for studying prevention. With the goals of developing a predictive model for
14
15 ulceration and overall prevention strategy in mind, this study aims to identify risk factors
16
17 associated with development of the fVLU. While certain risk factors have been described (Table
18
19 1), they are based primarily on either retrospective analyses that compared people with any
20
21 VLU (i.e. first or recurrent) to the general population or on expert opinion.
22
23
24

25
26 Furthermore, associations between VLU occurrence and certain medical conditions (18),
27
28 medications (19, 20), and other parameters (21-23) have been made, but the directionality of
29
30 the association is not clear. Although these data are informative, they may not be clinically
31
32 useful. A need exists to distinguish risk factors for CVI and for fVLU, as only a small minority of
33
34 patients with CVI proceed to develop a fVLU (24). Particular risk factors specific for the fVLU are
35
36 not known, and to our knowledge no study has prospectively tracked development of the fVLU.
37
38
39

40
41 Therefore, the primary aim of this research is to answer a simple yet extremely complex
42
43 clinical question: in a patient presenting with signs and symptoms of CVI, what are the risk
44
45 factors that will help predict development of a fVLU? Once these potential risk factors have
46
47 been elucidated, appropriate interventions can then be pursued.
48
49
50

51 52 **Primary Objective**

53
54
55
56
57
58
59
60

1. Characterize risk factors associated with developing fVLU in people with CVI.

Secondary Objectives

2. Develop 3- and 5-year predictive models for risk of developing fVLU in patients with signs and symptoms of CVI.
3. Estimate the incidence of fVLU in people with CVI.

Methods and Analysis:

Geographical Context

Subjects will represent a diverse group from all over southeastern Florida primarily, with the vast majority coming from Miami-Dade, Broward, and Palm Beach Counties in the United States.

Study population

The VEINS Cohort will include both men and women ages 18-95. Any adult who has had reflux detected on venous duplex ultrasound of the lower extremities is potentially eligible. Patients who have undergone venous duplex studies for any indication will be considered. Exclusion criteria include age under 18, inability to provide consent over the phone, and history of venous ulcer prior to duplex study date.

Recruitment of Participants

1
2
3 Subjects will be recruited from a database of the University of Miami Hospital
4 and Clinic's vascular laboratory. The database, which goes back to July 2011, will be
5
6 queried for all patients who were found to have reflux of greater than 0.5 seconds on
7
8 venous duplex ultrasound of the lower extremities. After reflux has been noted from the
9
10 duplex study report, the subject's chart will be reviewed in the Electronic Medical
11
12 Record (EMR) to ascertain basic contact information. For this part of the study, a privacy
13
14 waiver for recruitment purposes has been approved by the local institutional review
15
16 board (IRB). The investigators will then call potential subjects by phone. The subjects will
17
18 provide a verbal phone consent for a phone survey and further chart review of potential
19
20 risk factors. During the verbal informed consent, all aspects of the study will be
21
22 reviewed, including: why subjects were selected, researcher goals, procedures, relevant
23
24 risks, benefits, and subjects' rights. It is anticipated that a large portion of the study
25
26 population is Spanish speaking. The verbal informed consent and survey have both been
27
28 translated to Spanish and will be administered by Spanish speaking research staff, with
29
30 the help of an interpreter as needed. Once consent is obtained and inclusion criteria
31
32 confirmed, subjects will be enrolled into the cohort.
33
34
35
36
37
38
39
40
41
42
43
44

45 **Sample size**

46
47 There are approximately 2,500 lower extremity venous duplex ultrasound reports in the
48
49 database that detected reflux going back to its inception in July 2011. In recent years,
50
51 approximately 500 duplex studies that find reflux have been performed annually. Thus, over the
52
53 next 5 years, we expect approximately 2,500 additional subjects will be potentially eligible to
54
55
56
57
58
59
60

1
2
3 enter the cohort. Given the paucity of data available on the incidence of fVLU, we will attempt
4
5 to recruit as many subjects as possible.
6
7
8
9

10 **Study design – Overview**

11
12 This protocol is for a longitudinal cohort study with retrospective and prospective
13 components. The methodology for building the cohort and following subjects is outlined in
14
15 **Figure 1.** The aim throughout is to identify subjects with venous reflux documented on
16 ultrasound prior to the development of fVLU. Any subject who reports a history of an ulcer
17 prior to the date of reflux study will be excluded from the cohort. The retrospective part of the
18 study will cover all patients currently in the database. If a subject went on to develop a fVLU
19 subsequent to the time of duplex study (i.e. after reflux was documented but before first
20 contact by the investigators), he/she will not be followed in any prospective manner. Instead,
21 only an entry survey will be administered and the subject's participation will end (see "End
22 Point and Follow-up" below). The prospective part of this study will include any subject who
23 met inclusion criteria but has not yet developed a VLU. Regardless of when subjects enter the
24 cohort, they will be followed prospectively for five years or until the occurrence of an ulcer,
25 whichever occurs first. Any subject who begins in the retrospective cohort can continue into the
26 prospective cohort so long as the fVLU has not developed. New subjects will be continuously
27 recruited as new patients come through the vascular lab for venous studies. We plan to recruit
28 new subjects for at least five years, though we hope to have the option of extending this
29 enrollment period and overall study duration depending on availability of resources.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

End Point and Follow-up

The endpoint of this study is development of fVLU, after which subjects will exit the cohort. If a subject has no history of fVLU, he/she will be contacted by phone for a follow-up survey every 3 months until the development of fVLU. At this time, the intention is that subjects will be followed for at least 5 years.

Data collection and management

In all cases, data will be collected via three sources: venous duplex ultrasound report, phone survey, and patient chart in the EMR. Venous duplex ultrasound reports will be accessed from a secure electronic database housed in the University of Miami Hospital and Clinic's vascular laboratory. For the phone survey, a script with exact wording for all questions and instructions has been created. Data on specific variables of interest will be ascertained from each source as outlined in Table 2. A comprehensive initial assessment form and a follow-up form have been designed. These forms are quite similar, except that the follow-up form omits questions on unchanging historical and demographic data.

All data will be entered and stored electronically in REDCap (Research Electronic Data Capture), a secure, web-based application that facilitates creation and management of data collection instruments, monitoring of data quality, and statistical analysis of data (25). This software has commonly been used for epidemiological research, including similar cohort studies (26). All investigators will be trained in data entry by the REDCap study administrator and must demonstrate proficiency with mock patients and data entry before being granted access to data collection forms.

Evaluation of study endpoint – photo of wound

If a subject reports development of fVLU, investigators will seek to obtain a photo in the patient chart or request that the subject submits a picture of the wound via secure email. We have developed a protocol for evaluating images received, which involves independent evaluation by two investigators. They will first confirm presence of a wound, then determine if this can be considered a VLU: yes, no, or indeterminate. In cases of disagreement, the case will be presented to a third wound expert (RSK) for final determination. Subjects will then be encouraged to see us in clinic. While a photograph of the wound is an optional step in the study protocol, it can help validate that the wound is a VLU based on location and appearance. In cases where visual evidence is not available, ulcer validation will be supported by key questions regarding wound characteristics, such as location and duration. Moreover, there is data supporting the ability of patients to correctly self-assess the status of their chronic wounds with up to 97% accuracy when compared to expert evaluation (27).

Pilot Study

A pilot study of 70 potential subjects was carried out. The first 10 venous duplex studies to report reflux from each year of the database's existence (2011-2017) were used. The purpose of this pilot study was to give investigators the chance to determine how well the phone survey and data collection forms performed with a variety of real subjects, and to discuss any changes that should be made. Only minor technical changes in data coding were

1
2
3 made. Of the 70 patients that were called, 22 were reached over the phone, 20 of whom
4
5 enrolled in the study.
6
7
8
9

10 **Statistical analysis of data**

11
12 For purpose of analysis the data will be de-identified and exported from Redcap into IBM SPSS
13
14 Statistics for Windows (IBM Corporation, Armonk, NY, USA). Summary estimate and confidence
15
16 intervals will be calculated. In order to estimate the time from venous reflux documentation to
17
18 fVLU, Kaplan Meier survival curves will be constructed. Cox proportional hazard regression
19
20 models will be constructed to investigate possible risk factors.
21
22
23
24
25
26
27

28 **Patient and public involvement:**

29
30 Patients and the general public were not involved in the development of the research question,
31
32 outcome measures, or protocol design.
33
34
35
36
37

38 **Discussion**

39
40 The aim of this study is to develop a cohort of patients with proven venous reflux that
41
42 can be followed prospectively until the development of a venous leg ulcer. In doing so, we hope
43
44 to shed some light on who, of the millions of people with CVI, is at greatest risk of developing a
45
46 fVLU. Previous studies have looked at recurrence rates and associated risk factors regarding
47
48 venous ulcers, but data regarding fVLU is quite limited. In addition, VLU incidence data
49
50 collected from the cohort will be informative, as the only incidence data available has been
51
52 inferred from retrospective analyses. The VEINS Cohort study seeks to determine, in a
53
54
55
56
57
58
59
60

1
2
3 prospective fashion, the roles of traditional CVI risk factors and novel risk or protective factors
4
5 in the development of fVLU. Where associations are detected, further studies will be pursued
6
7 that seek to elucidate the nature of the association. Furthermore, in identifying particular risk
8
9 factors and/or protective factors, we hope to develop a predictive model with risk scores for
10
11 the likelihood of fVLU development within 3 and 5 years of clinically significant CVI. Of note,
12
13 this study does not address time in relation to initial development of CVI, but rather time from
14
15 documentation of CVI on venous duplex ultrasound. Though lead time bias could impact our
16
17 analyses, lower extremity ultrasounds looking for reflux are typically only performed when CVI
18
19 becomes clinically significant, which is usually concurrent with the first time a patient sees a
20
21 doctor for leg problems.
22
23
24
25
26

27
28 Implementing early interventions that delay or prevent the development of a chronic
29
30 and morbid condition is the guiding principle behind these efforts. In doing so, the whole of
31
32 society benefits both economically and socially from a happier and healthier population.
33
34
35
36

37 **Potential Benefit to subjects:**

38
39
40 While there is no direct benefit to subjects, being asked about their health status
41
42 by a member of the research team every three months may raise the subjects'
43
44 awareness of their health. Additionally, if a patient develops an ulcer while in the
45
46 cohort, he/she will be referred to a wound clinic for appropriate management and
47
48 wound care.
49
50
51
52
53
54

55 **Ethics and Dissemination:**

Ethical aspects

All aspects of this study, including verbal informed consent, data collection, and photo acquisition, have been approved by the University of Miami Institutional Review Board. The Primary Investigator has extensive training and experience in clinical research and relevant bioethics. The research staff will include a team of primary researchers that have extensive qualifications and expertise to lead the study. All study staff are trained and routinely re-educated about the ethical conduct of human subject research. There are no anticipated physical, social, legal or economic risks associated with the study. There is minimal risk of breach of confidentiality. No vulnerable populations are specifically targeted in this study. Pregnant women will not be excluded.

Data protection

All subject-specific data will be kept confidential in a password-protected University desktop that can only be accessed by investigators. Study offices are kept locked and are protected by around-the-clock University of Miami security services. All records containing personal health information will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available. De-identified collected data may be used for future analysis and publication.

Dissemination

We hope to present the results of this study to the scientific community at conferences and in peer-reviewed journals.

1
2
3 **Contributorship Statement:** All authors, including Joshua S. Mervis, Robert S. Kirsner, and
4
5 Hadar Lev-Tov, made substantial contributions to the conception and design of this protocol. All
6
7 authors have critically read this manuscript and have made their revisions, and they have now
8
9 all approved this final version for submission. All authors agree to be accountable for the future
10
11 integrity of this study.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Risk factors for VLU (Vivas *et al.*, 2016)(1)

Age older than 55 years
Family history of CVI
Higher body mass index
History of pulmonary embolism
History of superficial/deep venous thrombosis
Lower extremities skeletal or joint disease
Higher number of pregnancies
Parental history of ankle ulcers
Physical inactivity
Ulcer history
Severe lipodermatosclerosis
Venous reflux in deep veins

VLU = venous leg ulcer

CVI = chronic venous insufficiency

For peer review only

Table 2: Variables of interest with corresponding data source

<i>Venous duplex ultrasound report:</i>	<i>Phone survey:</i>	<i>Patient chart:</i>
Study date	Race	Sex
Study indication	Ethnicity	Height
Reflux location(s)	History of VLU (including ulcer start date)	Weight
Reflux time(s)	Limitation of ankle movement	Venous dermatitis
Presence of DVT or superficial vein thrombosis	Mobility (i.e. use of a wheelchair or walker)	Lipodermatosclerosis
	History of DVT or PE	Atrophie blanche
	History of varicose veins	Past medical and surgical history
	History of leg swelling	Ulcer photograph
	Chronic itch of lower extremities	
	Chronic rash of lower extremities	
	Lower extremity vein procedures	
	Lower extremity artery procedures	
	Use of compression on lower extremities	
	Elevation of legs when sleeping	
	Number of pregnancies	
	Other past medical and surgical history	
	Medications	
	Smoking history	
	Exercise	
	Family history of leg ulcers, swelling, or varicose veins	

VLU = venous leg ulcer

DVT = deep vein thrombosis

PE = pulmonary embolism

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Flowchart outlining the methodology for building the VEINS cohort and following subjects prospectively once they are enrolled

For peer review only

References:

1. Vivas A, Lev-Tov H, Kirsner RS. Venous Leg Ulcers. *Ann Intern Med.* 2016;165(3):ITC17-ITC32.
2. Alavi A, Sibbald RG, Phillips TJ, Miller OF, Margolis DJ, Marston W, et al. What's new: Management of venous leg ulcers: Approach to venous leg ulcers. *J Am Acad Dermatol.* 2016;74(4):627-40; quiz 41-2.
3. Singer AJ, Tassiopoulos A, Kirsner RS. Evaluation and Management of Lower-Extremity Ulcers. *N Engl J Med.* 2017;377(16):1559-67.
4. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F, Coordinators V. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. *Int Angiol.* 2012;31(2):105-15.
5. Lurie F, Comerota A, Eklof B, Kistner RL, Labropoulos N, Lohr J, et al. Multicenter assessment of venous reflux by duplex ultrasound. *J Vasc Surg.* 2012;55(2):437-45.
6. Liu YC, Margolis DJ, Isseroff RR. Does inflammation have a role in the pathogenesis of venous ulcers? A critical review of the evidence. *J Invest Dermatol.* 2011;131(4):818-27.
7. Van de Scheur M, Falanga V. Pericapillary fibrin cuffs in venous disease. A reappraisal. *Dermatol Surg.* 1997;23(10):955-9.
8. Falanga V, Kirsner R, Katz MH, Gould E, Eaglstein WH, McFalls S. Pericapillary fibrin cuffs in venous ulceration. Persistence with treatment and during ulcer healing. *J Dermatol Surg Oncol.* 1992;18(5):409-14.
9. Green J, Jester R, McKinley R, Pooler A. The impact of chronic venous leg ulcers: a systematic review. *J Wound Care.* 2014;23(12):601-12.
10. Ma H, O'Donnell TF, Rosen NA, Iafrati MD. The real cost of treating venous ulcers in a contemporary vascular practice. *J Vasc Surg Venous Lymphat Disord.* 2014;2(4):355-61.
11. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N. Burden of venous leg ulcers in the United States. *J Med Econ.* 2014;17(5):347-56.
12. Kurz X, Kahn SR, Abenham L, Clement D, Norgren L, Baccaglini U, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. *Venous Insufficiency Epidemiologic and Economic Studies.* *Int Angiol.* 1999;18(2):83-102.
13. Neumann HA, Cornu-Thénard A, Jünger M, Mosti G, Munte K, Partsch H, et al. Evidence-based (S3) guidelines for diagnostics and treatment of venous leg ulcers. *J Eur Acad Dermatol Venereol.* 2016.
14. Marklund B, Sülau T, Lindholm C. Prevalence of non-healed and healed chronic leg ulcers in an elderly rural population. *Scand J Prim Health Care.* 2000;18(1):58-60.
15. Maklebust JA, Margolis DJ. Venous leg ulcer risk factors: who will study the problem? *Adv Wound Care.* 1997;10(2):6, 8.
16. Burrows C, Miller R, Townsend D, Bellefontaine R, Mackean G, Orsted HL, et al. Best practice recommendations for the prevention and treatment of venous leg ulcers: update 2006. *Adv Skin Wound Care.* 2007;20(11):611-21; quiz 22-3.
17. Robson MC, Cooper DM, Aslam R, Gould LJ, Harding KG, Margolis DJ, et al. Guidelines for the prevention of venous ulcers. *Wound Repair Regen.* 2008;16(2):147-50.

18. Margolis DJ, Knauss J, Bilker W. Medical conditions associated with venous leg ulcers. *Br J Dermatol*. 2004;150(2):267-73.
19. Margolis DJ, Hoffstad O, Isseroff RR. Association between the use of beta-adrenergic receptor agents and the development of venous leg ulcers. *Arch Dermatol*. 2007;143(10):1275-80.
20. Bérard A, Kahn SR, Abenham L. Is hormone replacement therapy protective for venous ulcer of the lower limbs? *Pharmacoepidemiol Drug Saf*. 2001;10(3):245-51.
21. Abbade LP, Lastória S, Rollo HeA. Venous ulcer: clinical characteristics and risk factors. *Int J Dermatol*. 2011;50(4):405-11.
22. Robertson L, Lee AJ, Gallagher K, Carmichael SJ, Evans CJ, McKinstry BH, et al. Risk factors for chronic ulceration in patients with varicose veins: a case control study. *J Vasc Surg*. 2009;49(6):1490-8.
23. Vlajinac H, Marinkovic J, Maksimovic M, Radak D. Factors related to venous ulceration: a cross-sectional study. *Angiology*. 2014;65(9):824-30.
24. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. *J Epidemiol Community Health*. 1999;53(3):149-53.
25. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-81.
26. Blumenberg C, Barros AJ. Electronic data collection in epidemiological research. The use of REDCap in the Pelotas birth cohorts. *Appl Clin Inform*. 2016;7(3):672-81.
27. Yim E, Van Driessche F, Baquerizo Nole KL, Kirsner RS. Patient self-assessment of chronic wounds. *Wound Repair Regen*. 2014;22(5):683-4.




Figure 1: Flowchart outlining the methodology for building the VEINS cohort and following subjects prospectively once they are enrolled

309x337mm (300 x 300 DPI)

BMJ Open

Protocol for a longitudinal cohort study: Determination of risk factors for the development of first venous leg ulcer in people with chronic venous insufficiency, the VEINS (Venous Insufficiency in South Florida) Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-023313.R2
Article Type:	Protocol
Date Submitted by the Author:	02-Nov-2018
Complete List of Authors:	Mervis, Joshua; University of Miami School of Medicine, Dermatology and Cutaneous Surgery Kirsner, Robert; University of Miami School of Medicine, Dermatology and Cutaneous Surgery Lev-Tov, Hadar; University of Miami School of Medicine, Dermatology and Cutaneous Surgery
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Dermatology, General practice / Family practice, Surgery, Cardiovascular medicine
Keywords:	Chronic venous insufficiency, Venous leg ulcer, Longitudinal cohort study, Primary prevention, venous reflux

SCHOLARONE™
Manuscripts

Protocol for a longitudinal cohort study: Determination of risk factors for the development of first venous leg ulcer in people with chronic venous insufficiency, the VEINS (Venous Insufficiency in South Florida) Cohort

Joshua Mervis¹, B.A.; Robert S. Kirsner¹, M.D.; Ph.D.; Hadar Lev-Tov¹, M.D.

¹Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida

*Address for correspondence:

Hadar Lev-Tov, M.D.
Department of Dermatology & Cutaneous Surgery
University of Miami Miller School of Medicine
1600 NW 10th Avenue, Room 2023A
Miami, FL, 33136
U.S.A.
Phone: 305-243-6734
Email: hlevtov@med.miami.edu

Word Count: 2,646

Reference Count: 27

Figure Count: 1

Table Count: 2

Funding Sources: This study received NO specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest: The authors of this protocol have NO conflict of interest to declare.

Prior Presentation: The authors declare that this protocol has NOT been published previously.

Contributorship Statement: All authors, including Joshua S. Mervis, Robert S. Kirsner, and Hadar Lev-Tov, made substantial contributions to the conception and design of this

1
2
3 protocol. All authors have critically read this manuscript and have made their revisions,
4
5 and they have now all approved this final version for submission. All authors agree to be
6
7 accountable for the future integrity of this study.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract:

Introduction: Chronic venous insufficiency (CVI) affects up to one third of the adult population yet venous leg ulcers (VLU), a significant complication of CVI, only affect 1-2% of adults in the United States. Why some develop VLU and others do not is unclear. VLU have a significant impact on quality of life and are extremely costly and difficult to treat. Moreover, VLU prevalence is increasing, doubling in the last 20 years. In order to characterize the differences between people with CVI and those who ultimately develop VLU, we aim to set up the unique Venous Insufficiency in South Florida (VEINS) cohort.

Methods and analysis: Subjects will be recruited from the University of Miami Hospital and Clinic's vascular lab database, which began in July 2011. Any adult age 18-95 who has had venous reflux detected on duplex ultrasound of the lower extremities is included. Approximately 2,500 patients are already in the database that meet these criteria, with an estimated 2,500 additional potential subjects to be recruited from the vascular lab database over the next five years. Subjects with history of VLU prior to duplex study date will be excluded. Data will be collected via review of the Doppler study report, patient phone interview, and review of the electronic medical record. Subjects will be contacted for follow-up every 3 months for at least 5 years until the study endpoint, development of first VLU (fVLU), is reached. In order to estimate the time from reflux documentation to fVLU, Kaplan Meier survival curves will be constructed. Cox proportional hazard regression models will be constructed to investigate possible risk factors.

1
2
3 **Ethics and dissemination:** This study is approved by the University of Miami's
4 Institutional Review Board (IRB). We hope to present the results of this study to
5
6 the scientific community at conferences and in peer-reviewed journals.
7
8
9

10
11
12
13
14
15 **Keywords:** Venous leg ulcer, Chronic venous insufficiency, primary prevention,
16 cohort study
17
18
19

20 21 22 23 24 25 **Strengths and Limitations:**

- 26
27 • To our knowledge, this study is the first that seeks to prospectively track
28 development of the fVLU among a population of subjects with CVI.
29
- 30
31 • The VEINS cohort will describe the natural history of CVI leading to fVLU, reveal
32 specific risk factors for the development of fVLU, and allow for the development
33 of 3- and 5-year predictive models for fVLU occurrence.
34
- 35
36 • The data obtained from this study will support the development of VLU
37 prevention strategies.
38
- 39
40 • This study does not address time in relation to initial development of CVI, but
41 rather time from documentation of CVI on venous duplex ultrasound, typically the
42 point at which CVI becomes clinically significant.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protocol for a longitudinal cohort study: Determination of risk factors for the development of first venous leg ulcer in people with chronic venous insufficiency, the VEINS (Venous Insufficiency in South Florida) Cohort

Introduction

Background:

Chronic ulcers of the lower extremities affect 1-2% of adults in the United States (1-3). Of these ulcers, around 70% are due to venous disease alone, while 20% are due to arterial or mixed arteriovenous disease (2). Venous leg ulcers (VLU) are wounds that typically occur on the lower third of the leg between the ankle and knee, often referred to as the “gaiter area,” in the setting of chronic venous insufficiency (CVI). In the United States, roughly a third of the adult population is likely to have CVI, while worldwide prevalence estimates are up to 60% (4). CVI is characterized by sustained ambulatory venous pressure (aka venous hypertension) and by reflux on Doppler ultrasound. Reflux is typically defined as retrograde blood flow in the lower extremities greater than 0.5 seconds after provocation (5). Typical causes of CVI include valvular defects, which may be acquired or genetic, ineffective calf muscle pump action, and obstruction from deep vein thrombosis (1, 2). The pathophysiology of VLU remains unclear, though various observation-based hypotheses implicating pericapillary fibrin cuffing, endovascular trapping of oxygen and nutrients, inflammatory cell infiltrates, cytokine trapping, and metalloproteinase dysregulation have all been areas of extensive research (6-8).

1
2
3 VLU often have a very significant impact on a patient's quality of life (9). Compared with
4
5
6 matched controls, patients with VLU have more comorbid conditions, miss more days of work,
7
8
9 and use more medical resources (10, 11). While numerous advancements in treatment, such as
10
11
12 cellular and acellular skin equivalents and biomaterials, have been made in recent years (1),
13
14
15 VLU prevalence seems to be increasing. The estimated prevalence of VLU has doubled in the
16
17
18 last 20 years from 0.3% to 0.6% in adults under 65 and is up to 2.2% in adults over 65 (10, 12).
19
20
21 European epidemiologic data has shown similar prevalence rates among these age groups,
22
23
24 while revealing that VLU prevalence is even higher at 4-5% in individuals older than 80 years
25
26
27 (13) and may exceed 12% among certain elderly populations. (14)

28
29
30 Moreover, the costs associated with VLU have been increasing and represent a great
31
32
33 burden for both the patient and public health system. Over the last 30 years, the estimated cost
34
35
36 of treating a single, chronic VLU has more than tripled to \$34,000 today (10, 12). Likewise, the
37
38
39 annual cost of VLU treatment in the United States has risen from around \$3 billion in 1987 to
40
41
42 \$15 billion in 2011 ((11).

43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Rationale:

With an aging population, it is likely that VLU prevalence will continue to rise, with more
ulcers occurring in older, sicker patients who are costlier to treat. Despite the significant
morbidity, high costs, and continued difficulty in healing of VLU, little attention has been given
to primary prevention. Thus, a paradigm shift, away from wholesale investment in advanced
interventions and toward prevention, is warranted. The idea that a greater emphasis on VLU
prevention is needed is not new, going back to at least 1997 (15). Nonetheless, no studies to

1
2
3 date have focused on prevention of the first VLU (fVLU). Without this data, society and
4
5 summary guidelines on VLU have not been able to make recommendations regarding primary
6
7 prevention (1, 2, 16, 17).
8
9

10
11 Given that the pathophysiology of VLUs is not well-understood, risk factor analysis is a
12
13 sensible strategy for studying prevention. With the goals of developing a predictive model for
14
15 ulceration and overall prevention strategy in mind, this study aims to identify risk factors
16
17 associated with development of the fVLU. While certain risk factors have been described (1)
18
19 (Table 1), they are based primarily on either retrospective analyses that compared people with
20
21 any VLU (i.e. first or recurrent) to the general population or on expert opinion.
22
23

24
25 Furthermore, associations between VLU occurrence and certain medical conditions (18),
26
27 medications (19, 20), and other parameters (21-23) have been made, but the directionality of
28
29 the association is not clear. Although these data are informative, they may not be clinically
30
31 useful. A need exists to distinguish risk factors for CVI and for fVLU, as only a small minority of
32
33 patients with CVI proceed to develop a fVLU (24). Particular risk factors specific for the fVLU are
34
35 not known, and to our knowledge no study has prospectively tracked development of the fVLU.
36
37

38
39 Therefore, the primary aim of this research is to answer a simple yet extremely complex
40
41 clinical question: in a patient presenting with signs and symptoms of CVI, what are the risk
42
43 factors that will help predict development of a fVLU? Once these potential risk factors have
44
45 been elucidated, appropriate interventions can then be pursued.
46
47
48
49

50 51 52 **Primary Objective** 53 54 55 56 57 58 59 60

1. Characterize risk factors associated with developing fVLU in people with CVI.

Secondary Objectives

2. Develop 3- and 5-year predictive models for risk of developing fVLU in patients with signs and symptoms of CVI.
3. Estimate the incidence of fVLU in people with CVI.

Methods and Analysis:

Geographical Context

Subjects will represent a diverse group from all over southeastern Florida primarily, with the vast majority coming from Miami-Dade, Broward, and Palm Beach Counties in the United States.

Study population

The VEINS Cohort will include both men and women ages 18-95. Any adult who has had reflux detected on venous duplex ultrasound of the lower extremities is potentially eligible. Patients who have undergone venous duplex studies for any indication will be considered. Exclusion criteria include age under 18, inability to provide consent over the phone, and history of venous ulcer prior to duplex study date.

Recruitment of Participants

1
2
3 Subjects will be recruited from a database of the University of Miami Hospital
4
5 and Clinic's vascular laboratory. The database, which goes back to July 2011, will be
6
7 queried for all patients who were found to have reflux of greater than 0.5 seconds on
8
9 venous duplex ultrasound of the lower extremities. After reflux has been noted from the
10
11 duplex study report, the subject's chart will be reviewed in the Electronic Medical
12
13 Record (EMR) to ascertain basic contact information. For this part of the study, a privacy
14
15 waiver for recruitment purposes has been approved by the local institutional review
16
17 board (IRB). The investigators will then call potential subjects by phone. The subjects will
18
19 provide a verbal phone consent for a phone survey and further chart review of potential
20
21 risk factors. During the verbal informed consent, all aspects of the study will be
22
23 reviewed, including: why subjects were selected, researcher goals, procedures, relevant
24
25 risks, benefits, and subjects' rights. It is anticipated that a large portion of the study
26
27 population is Spanish speaking. The verbal informed consent and survey have both been
28
29 translated to Spanish and will be administered by Spanish speaking research staff, with
30
31 the help of an interpreter as needed. Once consent is obtained and inclusion criteria
32
33 confirmed, subjects will be enrolled into the cohort.
34
35
36
37
38
39
40
41
42
43
44

45 **Sample size**

46
47 There are approximately 2,500 lower extremity venous duplex ultrasound reports in the
48
49 database that detected reflux going back to its inception in July 2011. In recent years,
50
51 approximately 500 duplex studies that find reflux have been performed annually. Thus, over the
52
53 next 5 years, we expect approximately 2,500 additional subjects will be potentially eligible to
54
55
56
57
58
59
60

1
2
3 enter the cohort. Given the paucity of data available on the incidence of fVLU, we will attempt
4
5 to recruit as many subjects as possible.
6
7
8
9

10 **Study design – Overview**

11
12 This protocol is for a longitudinal cohort study with retrospective and prospective
13 components. The methodology for building the cohort and following subjects is outlined in
14
15 **Figure 1.** The aim throughout is to identify subjects with venous reflux documented on
16
17 ultrasound prior to the development of fVLU. Any subject who reports a history of an ulcer
18
19 prior to the date of reflux study will be excluded from the cohort. The retrospective part of the
20
21 study will cover all patients currently in the database. If a subject went on to develop a fVLU
22
23 subsequent to the time of duplex study (i.e. after reflux was documented but before first
24
25 contact by the investigators), he/she will not be followed in any prospective manner. Instead,
26
27 only an entry survey will be administered and the subject's participation will end (see "End
28
29 Point and Follow-up" below). The prospective part of this study will include any subject who
30
31 met inclusion criteria but has not yet developed a VLU. Regardless of when subjects enter the
32
33 cohort, they will be followed prospectively for five years or until the occurrence of an ulcer,
34
35 whichever occurs first. Any subject who begins in the retrospective cohort can continue into the
36
37 prospective cohort so long as the fVLU has not developed. New subjects will be continuously
38
39 recruited as new patients come through the vascular lab for venous studies. We plan to recruit
40
41 new subjects for at least five years, though we hope to have the option of extending this
42
43 enrollment period and overall study duration depending on availability of resources.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

End Point and Follow-up

The endpoint of this study is development of fVLU, after which subjects will exit the cohort. If a subject has no history of fVLU, he/she will be contacted by phone for a follow-up survey every 3 months until the development of fVLU. At this time, the intention is that subjects will be followed for at least 5 years.

Data collection and management

In all cases, data will be collected via three sources: venous duplex ultrasound report, phone survey, and patient chart in the EMR. Venous duplex ultrasound reports will be accessed from a secure electronic database housed in the University of Miami Hospital and Clinic's vascular laboratory. For the phone survey, a script with exact wording for all questions and instructions has been created. Data on specific variables of interest will be ascertained from each source as outlined in Table 2. A comprehensive initial assessment form and a follow-up form have been designed. These forms are quite similar, except that the follow-up form omits questions on unchanging historical and demographic data.

All data will be entered and stored electronically in REDCap (Research Electronic Data Capture), a secure, web-based application that facilitates creation and management of data collection instruments, monitoring of data quality, and statistical analysis of data (25). This software has commonly been used for epidemiological research, including similar cohort studies (26). All investigators will be trained in data entry by the REDCap study administrator and must demonstrate proficiency with mock patients and data entry before being granted access to data collection forms.

Evaluation of study endpoint – photo of wound

If a subject reports development of fVLU, investigators will seek to obtain a photo in the patient chart or request that the subject submits a picture of the wound via secure email. We have developed a protocol for evaluating images received, which involves independent evaluation by two investigators. They will first confirm presence of a wound, then determine if this can be considered a VLU: yes, no, or indeterminate. In cases of disagreement, the case will be presented to a third wound expert (RSK) for final determination. Subjects will then be encouraged to see us in clinic. While a photograph of the wound is an optional step in the study protocol, it can help validate that the wound is a VLU based on location and appearance. In cases where visual evidence is not available, ulcer validation will be supported by key questions regarding wound characteristics, such as location and duration. Moreover, there is data supporting the ability of patients to correctly self-assess the status of their chronic wounds with up to 97% accuracy when compared to expert evaluation (27).

Pilot Study

A pilot study of 70 potential subjects was carried out. The first 10 venous duplex studies to report reflux from each year of the database's existence (2011-2017) were used. The purpose of this pilot study was to give investigators the chance to determine how well the phone survey and data collection forms performed with a variety of real subjects, and to discuss any changes that should be made. Only minor technical changes in data coding were

1
2
3 made. Of the 70 patients that were called, 22 were reached over the phone, 20 of whom
4
5 enrolled in the study.
6
7
8
9

10 **Statistical analysis of data**

11
12
13
14 For purpose of analysis the data will be de-identified and exported from Redcap into IBM SPSS
15
16 Statistics for Windows (IBM Corporation, Armonk, NY, USA). Summary estimate and confidence
17
18 intervals will be calculated. In order to estimate the time from venous reflux documentation to
19
20 fVLU, Kaplan Meier survival curves will be constructed. Cox proportional hazard regression
21
22 models will be constructed to investigate possible risk factors.
23
24
25
26

27 **Patient and public involvement:**

28
29
30 Patients and the general public were not involved in the development of the research question,
31
32 outcome measures, or protocol design.
33
34
35
36

37 **Discussion**

38
39
40 The aim of this study is to develop a cohort of patients with proven venous reflux that
41
42 can be followed prospectively until the development of a venous leg ulcer. In doing so, we hope
43
44 to shed some light on who, of the millions of people with CVI, is at greatest risk of developing a
45
46 fVLU. Previous studies have looked at recurrence rates and associated risk factors regarding
47
48 venous ulcers, but data regarding fVLU is quite limited. In addition, VLU incidence data
49
50 collected from the cohort will be informative, as the only incidence data available has been
51
52
53 inferred from retrospective analyses. The VEINS Cohort study seeks to determine, in a
54
55
56
57
58
59
60

1
2
3 prospective fashion, the roles of traditional CVI risk factors and novel risk or protective factors
4
5 in the development of fVLU. Where associations are detected, further studies will be pursued
6
7 that seek to elucidate the nature of the association. Furthermore, in identifying particular risk
8
9 factors and/or protective factors, we hope to develop a predictive model with risk scores for
10
11 the likelihood of fVLU development within 3 and 5 years of clinically significant CVI. Of note,
12
13 this study does not address time in relation to initial development of CVI, but rather time from
14
15 documentation of CVI on venous duplex ultrasound. Though lead time bias could impact our
16
17 analyses, lower extremity ultrasounds looking for reflux are typically only performed when CVI
18
19 becomes clinically significant, which is usually concurrent with the first time a patient sees a
20
21 doctor for leg problems.
22
23
24
25
26

27
28 Implementing early interventions that delay or prevent the development of a chronic
29
30 and morbid condition is the guiding principle behind these efforts. In doing so, the whole of
31
32 society benefits both economically and socially from a happier and healthier population.
33
34
35
36

37 **Potential Benefit to subjects:**

38
39
40 While there is no direct benefit to subjects, being asked about their health status
41
42 by a member of the research team every three months may raise the subjects'
43
44 awareness of their health. Additionally, if a patient develops an ulcer while in the
45
46 cohort, he/she will be referred to a wound clinic for appropriate management and
47
48 wound care.
49
50
51
52
53
54

55 **Ethics and Dissemination:**

Ethical aspects

All aspects of this study, including verbal informed consent, data collection, and photo acquisition, have been approved by the University of Miami Institutional Review Board. The Primary Investigator has extensive training and experience in clinical research and relevant bioethics. The research staff will include a team of primary researchers that have extensive qualifications and expertise to lead the study. All study staff are trained and routinely re-educated about the ethical conduct of human subject research. There are no anticipated physical, social, legal or economic risks associated with the study. There is minimal risk of breach of confidentiality. No vulnerable populations are specifically targeted in this study. Pregnant women will not be excluded.

Data protection

All subject-specific data will be kept confidential in a password-protected University desktop that can only be accessed by investigators. Study offices are kept locked and are protected by around-the-clock University of Miami security services. All records containing personal health information will be kept confidential and, to the extent permitted by the applicable laws and/or regulations, will not be made publicly available. De-identified collected data may be used for future analysis and publication.

Dissemination

We hope to present the results of this study to the scientific community at conferences and in peer-reviewed journals.

1
2
3 **Contributorship Statement:** All authors, including Joshua S. Mervis, Robert S. Kirsner, and
4
5 Hadar Lev-Tov, made substantial contributions to the conception and design of this protocol. All
6
7 authors have critically read this manuscript and have made their revisions, and they have now
8
9 all approved this final version for submission. All authors agree to be accountable for the future
10
11 integrity of this study.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Risk factors for VLU

Age older than 55 years
Family history of CVI
Higher body mass index
History of pulmonary embolism
History of superficial/deep venous thrombosis
Lower extremities skeletal or joint disease
Higher number of pregnancies
Parental history of ankle ulcers
Physical inactivity
Ulcer history
Severe lipodermatosclerosis
Venous reflux in deep veins

VLU = venous leg ulcer

CVI = chronic venous insufficiency

Table 2: Variables of interest with corresponding data source

<i>Venous duplex ultrasound report:</i>	<i>Phone survey:</i>	<i>Patient chart:</i>
Study date	Race	Sex
Study indication	Ethnicity	Height
Reflux location(s)	History of VLU (including ulcer start date)	Weight
Reflux time(s)	Limitation of ankle movement	Venous dermatitis
Presence of DVT or superficial vein thrombosis	Mobility (i.e. use of a wheelchair or walker)	Lipodermatosclerosis
	History of DVT or PE	Atrophie blanche
	History of varicose veins	Past medical and surgical history
	History of leg swelling	Ulcer photograph
	Chronic itch of lower extremities	
	Chronic rash of lower extremities	
	Lower extremity vein procedures	
	Lower extremity artery procedures	
	Use of compression on lower extremities	
	Elevation of legs when sleeping	
	Number of pregnancies	
	Other past medical and surgical history	
	Medications	
	Smoking history	
	Exercise	
	Family history of leg ulcers, swelling, or varicose veins	

VLU = venous leg ulcer

DVT = deep vein thrombosis

PE = pulmonary embolism

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Flowchart outlining the methodology for building the VEINS cohort and following subjects prospectively once they are enrolled

For peer review only

References:

1. Vivas A, Lev-Tov H, Kirsner RS. Venous Leg Ulcers. *Ann Intern Med.* 2016;165(3):ITC17-ITC32.
2. Alavi A, Sibbald RG, Phillips TJ, Miller OF, Margolis DJ, Marston W, et al. What's new: Management of venous leg ulcers: Approach to venous leg ulcers. *J Am Acad Dermatol.* 2016;74(4):627-40; quiz 41-2.
3. Singer AJ, Tassiopoulos A, Kirsner RS. Evaluation and Management of Lower-Extremity Ulcers. *N Engl J Med.* 2017;377(16):1559-67.
4. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F, Coordinators V. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. *Int Angiol.* 2012;31(2):105-15.
5. Lurie F, Comerota A, Eklof B, Kistner RL, Labropoulos N, Lohr J, et al. Multicenter assessment of venous reflux by duplex ultrasound. *J Vasc Surg.* 2012;55(2):437-45.
6. Liu YC, Margolis DJ, Isseroff RR. Does inflammation have a role in the pathogenesis of venous ulcers? A critical review of the evidence. *J Invest Dermatol.* 2011;131(4):818-27.
7. Van de Scheur M, Falanga V. Pericapillary fibrin cuffs in venous disease. A reappraisal. *Dermatol Surg.* 1997;23(10):955-9.
8. Falanga V, Kirsner R, Katz MH, Gould E, Eaglstein WH, McFalls S. Pericapillary fibrin cuffs in venous ulceration. Persistence with treatment and during ulcer healing. *J Dermatol Surg Oncol.* 1992;18(5):409-14.
9. Green J, Jester R, McKinley R, Pooler A. The impact of chronic venous leg ulcers: a systematic review. *J Wound Care.* 2014;23(12):601-12.
10. Ma H, O'Donnell TF, Rosen NA, Iafrati MD. The real cost of treating venous ulcers in a contemporary vascular practice. *J Vasc Surg Venous Lymphat Disord.* 2014;2(4):355-61.
11. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N. Burden of venous leg ulcers in the United States. *J Med Econ.* 2014;17(5):347-56.
12. Kurz X, Kahn SR, Abenham L, Clement D, Norgren L, Baccaglini U, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. *Venous Insufficiency Epidemiologic and Economic Studies.* *Int Angiol.* 1999;18(2):83-102.
13. Neumann HA, Cornu-Thénard A, Jünger M, Mosti G, Munte K, Partsch H, et al. Evidence-based (S3) guidelines for diagnostics and treatment of venous leg ulcers. *J Eur Acad Dermatol Venereol.* 2016.
14. Marklund B, Sülau T, Lindholm C. Prevalence of non-healed and healed chronic leg ulcers in an elderly rural population. *Scand J Prim Health Care.* 2000;18(1):58-60.
15. Maklebust JA, Margolis DJ. Venous leg ulcer risk factors: who will study the problem? *Adv Wound Care.* 1997;10(2):6, 8.
16. Burrows C, Miller R, Townsend D, Bellefontaine R, Mackean G, Orsted HL, et al. Best practice recommendations for the prevention and treatment of venous leg ulcers: update 2006. *Adv Skin Wound Care.* 2007;20(11):611-21; quiz 22-3.
17. Robson MC, Cooper DM, Aslam R, Gould LJ, Harding KG, Margolis DJ, et al. Guidelines for the prevention of venous ulcers. *Wound Repair Regen.* 2008;16(2):147-50.

18. Margolis DJ, Knauss J, Bilker W. Medical conditions associated with venous leg ulcers. *Br J Dermatol*. 2004;150(2):267-73.
19. Margolis DJ, Hoffstad O, Isseroff RR. Association between the use of beta-adrenergic receptor agents and the development of venous leg ulcers. *Arch Dermatol*. 2007;143(10):1275-80.
20. Bérard A, Kahn SR, Abenham L. Is hormone replacement therapy protective for venous ulcer of the lower limbs? *Pharmacoepidemiol Drug Saf*. 2001;10(3):245-51.
21. Abbade LP, Lastória S, Rollo HeA. Venous ulcer: clinical characteristics and risk factors. *Int J Dermatol*. 2011;50(4):405-11.
22. Robertson L, Lee AJ, Gallagher K, Carmichael SJ, Evans CJ, McKinstry BH, et al. Risk factors for chronic ulceration in patients with varicose veins: a case control study. *J Vasc Surg*. 2009;49(6):1490-8.
23. Vlajinac H, Marinkovic J, Maksimovic M, Radak D. Factors related to venous ulceration: a cross-sectional study. *Angiology*. 2014;65(9):824-30.
24. Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. *J Epidemiol Community Health*. 1999;53(3):149-53.
25. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42(2):377-81.
26. Blumenberg C, Barros AJ. Electronic data collection in epidemiological research. The use of REDCap in the Pelotas birth cohorts. *Appl Clin Inform*. 2016;7(3):672-81.
27. Yim E, Van Driessche F, Baquerizo Nole KL, Kirsner RS. Patient self-assessment of chronic wounds. *Wound Repair Regen*. 2014;22(5):683-4.




Figure 1: Flowchart outlining the methodology for building the VEINS cohort and following subjects prospectively once they are enrolled

309x337mm (300 x 300 DPI)